Brain stem cell injection aims to restore movement in Parkinson's
NCT ID NCT07212088
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a single injection of lab-grown dopamine-producing cells into the brains of 12 people with advanced Parkinson's disease. The goal is to see if the procedure is safe and if it can improve motor function and quality of life. Participants must be between 55 and 75 years old, have had Parkinson's for over 5 years, and experience daily 'off' periods despite medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALC01 therapy (iPSC-derived dopamine progenitor cells)
What this could lead to
If successful, this could point toward a cell-based treatment that restores dopamine function and improves motor symptoms in Parkinson's disease.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, so safety and feasibility are the main focus. The procedure involves brain surgery, which carries risks like bleeding or infection, and the cells may not survive or work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact